Evidence map›Paper›PMID 36721864›Full record

ArticleEFSA journal. European Food Safety Authority2023

Assessment of genetically modified maize GA21 × T25 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2016-137).

EFSA Panel on Genetically Modified Organisms (GMO), Ewen Mullins, Jean-Louis Bresson, Tamas Dalmay, Ian Crawford Dewhurst, Michelle M Epstein, Leslie George Firbank, Philippe Guerche, Jan Hejatko, Francisco Javier Moreno and 25 more

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

EFSA Panel on Genetically Modified Organisms (GMO)
Ewen Mullins
Jean-Louis Bresson
Tamas Dalmay
Ian Crawford Dewhurst
Michelle M Epstein
Leslie George Firbank
Philippe Guerche
Jan Hejatko
Francisco Javier Moreno
Hanspeter Naegeli
Fabien Nogué
Nils Rostoks
Jose Juan Sánchez Serrano
Giovanni Savoini
Eve Veromann
Fabio Veronesi
Fernando Álvarez
Michele Ardizzone
Giacomo De Sanctis
Yann Devos
Silvia Federici
Antonio Fernandez Dumont
Andrea Gennaro
José Ángel Gómez Ruiz
Tilemachos Goumperis
Dafni Maria Kagkli
Anna Lanzoni
Paolo Lenzi
Ana Martin Camargo
Franco Maria Neri
Nikoletta Papadopoulou
Konstantinos Paraskevopoulos
Tommaso Raffaello
Franz Streissl

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically modified maize GA21 × T25 was developed by crossing to combine two single events: GA21 and T25. The GMO Panel previously assessed the two single maize events and did not identify safety concerns. No new data on the single maize events were identified that could lead to modification of the original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the single maize events and of the newly expressed proteins in maize GA21 × T25 does not give rise to food and feed safety and nutritional concerns. The GMO Panel concludes that maize GA21 × T25, as described in this application, is as safe as its conventional counterpart and the non-GM reference varieties tested, and no post-market monitoring of food and feed is considered necessary. In the case of accidental release of viable maize GA21 × T25 grains into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize GA21 × T25. Post-market monitoring of food and feed is not considered necessary. The GMO Panel concludes that maize GA21 × T25 is as safe as its conventional counterpart and the non-GM reference varieties tested, with respect to potential effects on human and animal health and the environment.

Indexed as

GA21genetic engineeringGMmaize (Zea mays)mEPSPSPATT25

Identifiers

PMID36721864
PMCPMC9880721

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.